CPSI-1306 | CAS#1309793-47-2 | MIF antagonist

MedKoo Cat#: 563359 | Name: CPSI-1306

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CPSI-1306 is a antagonist of macrophage migration inhibitory factor (MIF).

Chemical Structure

CPSI-1306

CAS#1309793-47-2

Theoretical Analysis

MedKoo Cat#: 563359

Name: CPSI-1306

CAS#: 1309793-47-2

Chemical Formula: C15H16F2N2O3

Exact Mass: 310.1129

Molecular Weight: 310.30

Elemental Analysis: C, 58.06; H, 5.20; F, 12.25; N, 9.03; O, 15.47

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 350.00	2 Weeks
50mg	USD 600.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CPSI-1306; CPSI 1306; CPSI1306;

IUPAC/Chemical Name

2-[3-(2,4-Difluoro-phenyl)-4,5-dihydro-isoxazol-5-yl]-1-morpholin-4-yl-ethanone

InChi Key

GUWOSEVHCSNYFK-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H16F2N2O3/c16-10-1-2-12(13(17)7-10)14-8-11(22-18-14)9-15(20)19-3-5-21-6-4-19/h1-2,7,11H,3-6,8-9H2

SMILES Code

FC1=CC=C(C2=NOC(CC(N3CCOCC3)=O)C2)C(F)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

(±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).

In vitro activity:

A panel of human (MDA-MB-231, MDA-MB-468, SCP-2) and mouse (MVT-1) TNBC cells were treated with CPSI-1306 and cell viability was estimated by MTT assay. CPSI-1306 significantly reduced cell viability in nearly all TNBC cell lines (Fig. 4a). Reference: Cell Death Dis. 2020 Sep; 11(9): 774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498597/

In vivo activity:

Finally, oral administration of a small-molecule MIF antagonist, CPSI-1306, to outbred ICR mice following induction of NIDDM significantly lowered blood glucose levels in the majority of animals, which was also associated with a significant reduction in the levels of the proinflammatory cytokines IL-6 and TNF-alpha in the sera. Reference: FASEB J. 2010 Jul;24(7):2583-90. https://pubmed.ncbi.nlm.nih.gov/20203087/

	Solvent	mg/mL	mM
Solubility
	DMSO	22.3	71.99
	DMSO:PBS (pH 7.2) (1:4)	0.2	0.64
	DMF	30.0	96.68
	Ethanol	3.1	9.99

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 310.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Charan M, Das S, Mishra S, Chatterjee N, Varikuti S, Kaul K, Misri S, Ahirwar DK, Satoskar AR, Ganju RK. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. Cell Death Dis. 2020 Sep 17;11(9):774. doi: 10.1038/s41419-020-02992-y. PMID: 32943608; PMCID: PMC7498597. 2. Nagarajan P, Tober KL, Riggenbach JA, Kusewitt DF, Lehman AM, Sielecki T, Pruitt J, Satoskar AR, Oberyszyn TM. MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma. Mol Cancer Res. 2014 Sep;12(9):1292-302. doi: 10.1158/1541-7786.MCR-14-0255-T. Epub 2014 May 21. PMID: 24850900; PMCID: PMC4284200. 3. Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR, Rodriguez-Sosa M. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 2010 Jul;24(7):2583-90. doi: 10.1096/fj.09-147066. Epub 2010 Mar 4. PMID: 20203087.

In vitro protocol:

In vivo protocol:

1: Nagarajan P, Tober KL, Riggenbach JA, Kusewitt DF, Lehman AM, Sielecki T, Pruitt J, Satoskar AR, Oberyszyn TM. MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma. Mol Cancer Res. 2014 Sep;12(9):1292-302. doi: 10.1158/1541-7786.MCR-14-0255-T. Epub 2014 May 21. PubMed PMID: 24850900; PubMed Central PMCID: PMC4284200. 2: Kithcart AP, Cox GM, Sielecki T, Short A, Pruitt J, Papenfuss T, Shawler T, Gienapp I, Satoskar AR, Whitacre CC. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 2010 Nov;24(11):4459-66. doi: 10.1096/fj.10-162347. Epub 2010 Jul 12. PubMed PMID: 20624927; PubMed Central PMCID: PMC2974415. 3: Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR, Rodriguez-Sosa M. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 2010 Jul;24(7):2583-90. doi: 10.1096/fj.09-147066. Epub 2010 Mar 4. PubMed PMID: 20203087.